Zacks Research Issues Pessimistic Forecast for GSK Earnings

GSK plc (NYSE:GSK) – Research analysts at Zacks Research reduced their Q1 2026 EPS estimates for shares of GSK in a report issued on Wednesday, October 16th. Zacks Research analyst E. Bagri now forecasts that the pharmaceutical company will earn $1.11 per share for the quarter, down from their prior estimate of $1.12. The consensus estimate for GSK’s current full-year earnings is $4.14 per share.

A number of other equities analysts have also recently weighed in on the company. Barclays upgraded GSK to a “hold” rating in a report on Tuesday, August 27th. Jefferies Financial Group upped their price target on GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Argus upgraded GSK to a “strong-buy” rating in a report on Wednesday, August 7th. UBS Group cut GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Finally, Citigroup upgraded GSK to a “strong-buy” rating in a report on Monday, June 24th. Four equities research analysts have rated the stock with a hold rating, two have issued a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, GSK has a consensus rating of “Buy” and a consensus target price of $50.00.

GSK Stock Down 1.1 %

GSK opened at $38.54 on Friday. The firm has a 50 day moving average price of $41.44 and a 200 day moving average price of $41.26. The company has a market cap of $79.86 billion, a PE ratio of 13.96, a price-to-earnings-growth ratio of 1.30 and a beta of 0.65. GSK has a 1 year low of $33.67 and a 1 year high of $45.92. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82.

GSK (NYSE:GSK) last posted its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. The firm had revenue of $9.95 billion during the quarter, compared to the consensus estimate of $9.49 billion. GSK had a net margin of 12.87% and a return on equity of 51.48%.

Institutional Investors Weigh In On GSK

Several institutional investors and hedge funds have recently made changes to their positions in GSK. JTC Employer Solutions Trustee Ltd raised its position in shares of GSK by 71.3% during the 1st quarter. JTC Employer Solutions Trustee Ltd now owns 21,141,012 shares of the pharmaceutical company’s stock valued at $909,063,000 after acquiring an additional 8,800,822 shares in the last quarter. Primecap Management Co. CA raised its position in shares of GSK by 13.9% during the 2nd quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company’s stock valued at $558,689,000 after acquiring an additional 1,773,020 shares in the last quarter. Mondrian Investment Partners LTD raised its position in shares of GSK by 37.8% during the 1st quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company’s stock valued at $236,250,000 after acquiring an additional 1,512,442 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of GSK by 180.0% during the 1st quarter. Acadian Asset Management LLC now owns 2,219,798 shares of the pharmaceutical company’s stock valued at $95,129,000 after acquiring an additional 1,426,935 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of GSK during the 2nd quarter valued at approximately $52,487,000. 15.74% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other GSK news, major shareholder Plc Gsk bought 2,791,930 shares of GSK stock in a transaction dated Friday, September 27th. The stock was bought at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the purchase, the insider now owns 16,775,691 shares in the company, valued at $134,205,528. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 10.00% of the company’s stock.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 10th. Stockholders of record on Friday, August 16th were paid a dividend of $0.3843 per share. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 annualized dividend and a dividend yield of 3.99%. The ex-dividend date was Friday, August 16th. GSK’s dividend payout ratio is 55.80%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.